草酸艾司西酞普兰治疗稳定期慢性阻塞性肺疾病并发抑郁症的疗效  

Effect of escitalopram oxalate in treatment of stable chronic obstructive pulmonary disease complicated with depression

作　　者：梅建华 江瑞来 赵军飞[2] 赖根祥 王静 梅小美 陈娟 

机构地区：[1]浙江省丽水市第二人民医院老年科,丽水323000 [2]浙江省丽水市人民医院呼吸科,丽水323000 [3]浙江省丽水市第二人民医院心理科,丽水323000

出　　处：《中国临床药学杂志》2015年第2期81-85,共5页Chinese Journal of Clinical Pharmacy

摘　　要：目的观察草酸艾司西酞普兰治疗稳定期慢性阻塞性肺疾病(COPD)并发抑郁症的临床疗效及安全性。方法将82例稳定期COPD并发抑郁症患者随机分为观察组(41例)及对照组(41例)。对照组给予常规治疗,观察组在常规治疗基础上加草酸艾司西酞普兰抗抑郁治疗。对2组患者治疗后动脉血氧分压[pa(O2)]、肺功能、圣.乔治呼吸问题调查问卷(SGRQ)总分、呼吸困难量表(m MRC)分级、匹兹堡睡眠质量指数(PSQI)、6 min步行距离(6MWD)和Hamilton抑郁量表(HAMD)评分进行观察。结果观察组治疗后抑郁症临床显效率明显高于对照组,差异有统计学意义(P<0.05);观察组治疗后pa(O2)、FEV1%预计值、FEV1/FVC、m MRC分级、SGRQ总分、PSQI、6MWD和HAMD评分均优于对照组,差异有统计学意义(P<0.05或P<0.01);观察组和对照组不良反应发生率分别为22.0%、14.6%,差异无统计学意义(P>0.05)。结论草酸艾司西酞普兰治疗稳定期COPD并发抑郁症患者,能改善患者的抑郁症状,协同改善肺功能,提高患者的生活质量,且不良反应少,值得临床推广。AIM To observe the clinical efficacy and safety of escitalopram oxalate in the treatment of stable chronic obstructive pulmonary disease（COPD） complicated with depression. METHODS A total of 82 stable COPD pa- tients complicated with depression were randomly divided into observation group（41 patients） and control group（41 pa- tients）, respectively. The control group was given conventional treatment, and the observation group was given convention- al therapy plus escitalopram oxalate antidepressant treatment. The arterial partial pressure of oxygen [ P a （02）], pul- monary function, St. George poll breathing problems （SGRQ） score, dyspnea scale （mMRC） classification, the Pitts- burgh sleep quality index （PSQI）, 6 min walking distance （6MWD） and Hamilton depression scale （HAMD） score were observed after treatment in 2 groups. RESULTS After treatment the clinical depression in the observation group was sig- nificantly better than that in the control group, and the difference was statistically significant （ P 〈 0.05）. After treat- ment, p,（O2）, FEV1%, FEV1/FVC, mMRC classification of predicted value, the total score of SGRQ, PSQI, 6MWD and HAMD scores in the observation group were better than those in the control group, and the difference was statistically significant （P 〈 0.05 or P 〈 0.01）. The adverse drug reaction rates of observation group and control group were 22% and 14.6%, respectively, and the difference was not statistically significant （ P 〉 0.05）. CONCLUSION Escitalopram oxalate can be used to treat stable COPD complicated with depression patients, improve the patient＇s symptoms of depres-sion, collaborative improve lung function, improve the quality of life of patients with less adverse drug reaction, and is worth the clinical promotion.

关 键 词：草酸艾司西酞普兰 慢性阻塞性肺疾病 稳定期 抑郁障碍 肺功能 生活质量 

分 类 号：R563.9[医药卫生—呼吸系统] R749.4[医药卫生—内科学]